Calcipotriol plus betamethasone dipropionate aerosol foam provides superior efficacy vs. gel in patients with psoriasis vulgaris: randomized, controlled PSO‐ABLE study

@inproceedings{Paul2017CalcipotriolPB,
  title={Calcipotriol plus betamethasone dipropionate aerosol foam provides superior efficacy vs. gel in patients with psoriasis vulgaris: randomized, controlled PSO‐ABLE study},
  author={Carolyn Paul and Linda F Stein Gold and Frederic Cambazard and R. E. Kalb and D. Lowson and Bo Bang and C Griffiths},
  booktitle={Journal of the European Academy of Dermatology and Venereology : JEADV},
  year={2017}
}
BACKGROUND Fixed combination calcipotriol 50 μg/g (Cal) plus betamethasone 0.5 mg/g (BD) foam has been developed as a new treatment option for patients with psoriasis. METHODS The randomized, parallel-group, investigator-blinded Phase III, 12-week PSO-ABLE study compared the efficacy and safety of Cal/BD foam with Cal/BD gel. Patients aged ≥18 years with mild-to-severe psoriasis were randomized 4:4:1:1 to once-daily Cal/BD foam, Cal/BD gel, foam vehicle or gel vehicle (NCT02132936). The… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-8 of 8 extracted citations

Evidence-Based Psoriasis

Updates in Clinical Dermatology • 2018

Effect of Calcipotriol on IFN-γ-Induced Keratin 17 Expression in Immortalized Human Epidermal Keratinocyte Cells

Medical science monitor : international medical journal of experimental and clinical research • 2017
View 2 Excerpts

References

Publications referenced by this paper.
Showing 1-10 of 30 references

Enhanced in vitro skin penetration and antipsoriatic effect of fixed combination calcipotriol plus betamethasone dipropionate in an innovative foam vehicle

L Hollesen Basse, M Olesen, JP Lacour, C. Queille-Roussel
J Invest Dermatol • 2014